Trade Regulus Therapeutics Inc. - RGLS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.72 |
| Open | 1.73 |
| 1-Year Change | 35.16% |
| Day's Range | 1.72 - 1.79 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 26, 2024 | 1.74 | 0.01 | 0.58% | 1.73 | 1.79 | 1.71 |
| Jul 25, 2024 | 1.72 | 0.04 | 2.38% | 1.68 | 1.81 | 1.68 |
| Jul 24, 2024 | 1.70 | 0.04 | 2.41% | 1.66 | 1.76 | 1.66 |
| Jul 23, 2024 | 1.71 | 0.07 | 4.27% | 1.64 | 1.74 | 1.64 |
| Jul 22, 2024 | 1.66 | 0.00 | 0.00% | 1.66 | 1.67 | 1.62 |
| Jul 19, 2024 | 1.62 | -0.01 | -0.61% | 1.63 | 1.68 | 1.62 |
| Jul 18, 2024 | 1.65 | -0.02 | -1.20% | 1.67 | 1.73 | 1.61 |
| Jul 17, 2024 | 1.67 | -0.07 | -4.02% | 1.74 | 1.74 | 1.67 |
| Jul 16, 2024 | 1.74 | 0.01 | 0.58% | 1.73 | 1.78 | 1.66 |
| Jul 15, 2024 | 1.70 | 0.01 | 0.59% | 1.69 | 1.76 | 1.67 |
| Jul 12, 2024 | 1.66 | -0.08 | -4.60% | 1.74 | 1.80 | 1.66 |
| Jul 11, 2024 | 1.75 | 0.03 | 1.74% | 1.72 | 1.83 | 1.72 |
| Jul 10, 2024 | 1.72 | 0.06 | 3.61% | 1.66 | 1.75 | 1.66 |
| Jul 9, 2024 | 1.65 | -0.10 | -5.71% | 1.75 | 1.76 | 1.64 |
| Jul 8, 2024 | 1.72 | 0.11 | 6.83% | 1.61 | 1.76 | 1.61 |
| Jul 5, 2024 | 1.62 | -0.16 | -8.99% | 1.78 | 1.78 | 1.60 |
| Jul 3, 2024 | 1.73 | 0.03 | 1.76% | 1.70 | 1.78 | 1.68 |
| Jul 2, 2024 | 1.73 | -0.09 | -4.95% | 1.82 | 1.90 | 1.73 |
| Jul 1, 2024 | 1.86 | 0.15 | 8.77% | 1.71 | 1.86 | 1.69 |
| Jun 28, 2024 | 1.75 | -0.22 | -11.17% | 1.97 | 1.97 | 1.64 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Regulus Therapeutics Inc. Company profile
About Regulus Therapeutics Inc
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases. Its product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a kidney disease. The Company completed Phase I multiple-ascending dose (MAD) clinical trial. RGLS4326, an anti-miR targeting miR-17, is for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It is in Phase I clinical trial. The Company’s pre-clinical pipeline candidates include RGLS5579 and anti-miR-132. RGLS5579 is developing for the treatment of Glioblastoma and anti-miR-132 is developing for the treatment of non-alcoholic steatohepatitis. Its developing two undisclosed products under Cell Therapies program and Hepatitis B virus program.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Regulus Therapeutics Inc revenues decreased from $10M to $0K. Net loss increased 77% to $27.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects research increase of 16% to $16.5M (expense), general increase of 15% to $7.9M (expense), Stock-based Compensation in SGA increase of 9% to $2.1M (expense).
Equity composition
Common stock $.001 Par, 10/12, 200M auth., 34,130,393 issd. Insider Owns 67.04%.
| Industry: | Bio Therapeutic Drugs |
Suite 210
3545 John Hopkins Court
92121
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com